Core Insights - The success rate of developing first-in-class innovative drugs globally is low, with only 20%-30% of approved drugs achieving clinical value and market conversion in the US [1] - Biotech companies play a crucial role in overcoming research bottlenecks in the development of first-in-class drugs through deep scientific understanding and flexible application of technology [1][2] Group 1 - The development of innovative drugs is complex, as evidenced by the example of glucose kinase activators, where over 30 related molecules have entered clinical research without success [1] - Biotech companies have integrated new technologies into clinical stages earlier than traditional pharmaceutical companies, leading to breakthroughs in previously deemed "non-druggable" targets [2] - The evolution of drug molecular forms has seen biotech companies transition from small molecules to antibody drugs, and now to antibody-drug conjugates (ADCs), driving innovation in the pharmaceutical industry [2]